FinTechFunding

Immutep: Shares positive data from phase 2b AIPAC trial

Immutep Shares positive data from phase 2b AIPAC trial

  • Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase IIb AIPAC trial
  • The trial evaluated efti combined with paclitaxel chemotherapy compared to a placebo group in 227 patients with HER2-negative/HR-positive metastatic breast cancer
  • IMM says the higher immune response in efti patients compared to placebo patients confirms efti is activating the immune system and improving overall survival
  • The company is a globally active biotechnology company that is a leader in developing LAG-3 related immunotherapeutic products
  • The company is trading 7.58 per cent higher at 35.5 cents
Previous article
Intigriti: Raises Over €21.13M in Series B Funding
Next article
Elixir Energy: Completes Tim-2 well in Mongolia
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Mastercard Strengthens Payments Network with Agentic Transaction in Hong Kong

The innovative transaction marks a significant step in digital payments.Highlights: Mastercard successfully conducts an agentic transaction in Hong...
FinTech

OpenFX Raises $94M to Accelerate Growth in Fintech

The funding round aims to enhance OpenFX's innovative trading solutions.Highlights: OpenFX secures $94 million in funding.The investment will...
FinTech

Keyrock Strengthens Crypto Investment with $1.1 Billion Valuation

The crypto investment firm achieves a significant valuation milestone.Highlights: Keyrock hits a $1.1 billion valuation.Company focuses on crypto...
FinTech

Keyrock Strengthens Position with $1.1 Billion Valuation

Crypto investment specialist Keyrock secures significant market valuation boost.Highlights: Keyrock achieves a $1.1 billion valuation.Funding round aims to...